title: Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB)
authors.forename: R
authors.initials: R
authors.lastname: Sorio
authors.forename: E
authors.initials: E
authors.lastname: Galligioni
authors.forename: D
authors.initials: D
authors.lastname: Crivellari
authors.forename: R
authors.initials: R
authors.lastname: Talamini
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D007376:Interleukin-2; D014747:Vinblastine